



Office of Pharmacy Service Prior Authorization Criteria

Sirturo® (bedaquiline fumarate)

Requests for Sirturo will be authorized for:

1. Diagnosis of pulmonary multi-drug resistant tuberculosis **and**
2. Treatment given in combination with least 3 other drugs to which the patient's MDR-TB isolate has been shown to be susceptible *in vitro* **or**
3. If *in vitro* testing results are unavailable, treatment is given in combination with at least 4 other drugs to which the patient's MDR-TB isolate is likely to be susceptible and
4. Patient is ≥ 18 years if age,
5. Duration of treatment is 24 weeks and companions drugs are given for the entire period of treatment.
6. Patient is not concurrently taking drugs causing QT prolongation (amiodarone, chloroquine, azithromycin, clarithromycin, citalopram, disopyramide, etc) or is closely monitored if concurrent administration is necessary.

Janssen Therapeutics, Division of Janssen Products, LP Titusville, NJ 08560
© Janssen Products, LP 2012
Arizona Center for Research and Therapeutics May 2013

Reviewed and Approved
Drug Utilization Review Board
September 18, 2013